Plexxikon, Roche Near Catalyst For BRAF Inhibitor In Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
As its melanoma drug advances in the clinic, Plexxikon obtains rights to co-promote it in the U.S.
You may also be interested in...
Plexxikon Wins Tafinlar Patent Dispute Case Against Novartis
The Daiichi Sankyo affiliate successfully argued that Novartis willfully infringed two patents covering its discoveries in the BRAF inhibitor drug class, getting nearly $178m in damages and future royalties.
Researchers Coax Secrets, Possible Drug Targets From Multiple Myeloma Genome
The whole genome study suggests new targets for the incurable bone-marrow cancer, but even the nearest at hand could be years away from producing a therapeutic agent.
Researchers Coax Secrets, Possible Drug Targets From Multiple Myeloma Genome
The whole genome study suggests new targets for the incurable bone-marrow cancer, but even the nearest at hand could be years away from producing a therapeutic agent.